research

Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Neurocrine Biosciences announced plans to acquire Soleno Therapeutics in an April 2026 deal, expanding its rare disease pipeline. The acquisition targets Soleno’s lead asset, a late-stage treatment for Prader-Willi syndrome. CEO Kyle Gano and strategy VP Samir Siddhanti led the call, emphasizing the deal’s strategic fit with Neurocrine’s focus on underserved neurological and endocrine disorders. Financial and commercial leaders joined for Q&A. The transaction aims to accelerate Soleno’s clinical programs, leveraging Neurocrine’s commercial infrastructure. Analysts from top firms, including Goldman Sachs and JPMorgan, participated in the call. Neurocrine highlighted potential regulatory milestones, with Soleno’s candidate expected to advance toward FDA submission. The deal aligns with Neurocrine’s growth strategy in high-unmet-need markets. Slides detailing the acquisition’s terms and rationale were posted on Neurocrine’s investor website. The call underscored confidence in Soleno’s pipeline and integration plans.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.23K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Neurocrine Biosciences, Inc. (NBIX) M&A Call April 6, 2026 8:00 AM EDT Company Participants Todd Tushla - Vice President of Investor RelationsKyle Gano - CEO & DirectorSamir SiddhantiEric Benevich - Chief Commercial OfficerMatthew Abernethy - Chief Financial OfficerSanjay Keswani - Chief Medical Officer Conference Call Participants Charles Moore - Robert W. Baird & Co. Incorporated, Research DivisionPaul Matteis - Stifel, Nicolaus & Company, Incorporated, Research DivisionPhilip Nadeau - TD Cowen, Research DivisionBrian Abrahams - RBC Capital Markets, Research DivisionCorinne Jenkins - Goldman Sachs Group, Inc., Research DivisionCory Kasimov - Evercore ISI Institutional Equities, Research DivisionJoyce Zhou - JPMorgan Chase & Co, Research DivisionJoshua Schimmer - Cantor Fitzgerald & Co., Research DivisionMohit Bansal - Wells Fargo Securities, LLC, Research DivisionDavid Amsellem - Piper Sandler & Co., Research Division Presentation Operator Hello and welcome, everyone joining today's Neurocrine to acquire Soleno Therapeutics conference call. [Operator Instructions] Please note, this call is being recorded, and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead. Todd TushlaVice President of Investor Relations Good Monday morning, everyone. Thanks for joining the Neurocrine Biosciences call to discuss our planned acquisition of Soleno Therapeutics. On the call with me are Kyle Gano, Chief Executive Officer; and Samir Siddhanti, Vice President of Strategy and Business Development. Kyle and Samir will provide opening comments, and then we'll move to a Q&A session, where we'll also be joined by Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and Sanjay Keswani, our Chief Medical Officer. Note that we posted today's slides to the Investors section of our website at neurocrine.com that you can follow along with for the discussion. During today's call, we will be making

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.

Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Tags

Source Information